RxDoctor Payments Data

David Ross, MD

Internal Medicine · Dickson, TNNPI 1073516001

Payments from drug & device makers

$16,724in general payments, 2019–2025

Across 1,048 payments — averaging $15.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$2K
  • Lilly USA, LLC$2K
  • AstraZeneca$1K
  • Pfizer$1K
  • Amgen$1K
  • Boehringer Ingelheim$1K
  • plus $8K from 51 others

What the payments were for

  • Food & beverage$16,683100%
  • Education$400%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novo Nordisk121$1,973
Lilly USA, LLC90$1,557
AstraZeneca83$1,394
Pfizer102$1,275
Amgen81$1,160
Boehringer Ingelheim61$1,031
AbbVie(2 entities)56$872
Novartis48$792
Takeda Pharmaceuticals U.S.A., Inc.47$723
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC59$704
Bayer29$572
GSK37$564
Johnson & Johnson(2 entities)31$560
Lundbeck LLC18$426
Merck31$406
Sanofi-aventis U.S. LLC25$376
Otsuka America Pharmaceutical, Inc.13$244
Esperion Therapeutics, Inc.11$197
Exact Sciences9$150
Dexcom, Inc.7$144
Abbott6$120
Sumitomo Pharma America, Inc.7$113
Corcept Therapeutics5$107
Axsome Therapeutics, Inc.4$106
Paratek Pharmaceuticals, Inc.5$95
Biohaven Pharmaceuticals, Inc.5$86
Phathom Pharmaceuticals, Inc.4$69
Teva Pharmaceuticals USA, Inc.4$68
Astellas Pharma US Inc3$60
Acadia Pharmaceuticals Inc4$60
Eisai Inc.4$56
Nestle Healthcare Nutrition Inc.3$56
Arbor Pharmaceuticals, Inc.3$44
Sanofi Pasteur Inc.2$42
Corium, LLC2$41
Tris Pharma Inc2$33
VBI Vaccine (delaware) Inc.2$32
Amarin Pharma, Inc.2$30
Biohaven Pharmaceutical Holding Company Ltd.1$30
Harmony Biosciences LLC1$29
Jazz Pharmaceuticals Inc.2$28
Insulet Corporation1$27
Supernus Pharmaceuticals, Inc.2$25
Medtronic(2 entities)2$24
Shire North American Group Inc1$23
Boston Scientific1$22
Hologic Sales And Service, LLC1$20
Nevro Corp.1$19
Xeris Pharmaceuticals, Inc.1$18
Vertical Pharmaceuticals, LLC1$17
Shield Therapeutics Inc1$16
Ironshore Pharmaceuticals Inc.1$15
Adlon Therapeutics L.p.1$15
Genentech USA, Inc.1$15
Idorsia Pharmaceuticals US Inc1$14
Cranial Technologies, Inc1$14
Amneal Pharmaceuticals LLC1$13

How this compares

$16,724 in reported general payments places this provider in the 95th percentile of 2,216 internal medicine providers in Tennessee.

See all internal medicine providers in Tennessee

Medicare billing

Part B allowed, 2024
$332,933
Medicare patients
376
Services billed
15,663

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide165$199,643
JardianceEmpagliflozin172$165,578
MounjaroTirzepatide126$153,727
TrulicityDulaglutide78$89,484
EliquisApixaban91$70,301
FarxigaDapagliflozin Propanediol82$62,790
Trelegy ElliptaFluticasone/Umeclidin/Vilanter57$55,970
XareltoRivaroxaban35$33,507
KerendiaFinerenone30$27,616
Tresiba Flextouch U-200Insulin Degludec23$23,656
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog18$20,717
JanuviaSitagliptin Phosphate20$19,319
Xigduo XrDapaglifloz Propaned/Metformin25$16,137
Tresiba Flextouch U-100Insulin Degludec20$9,660
Breztri AerosphereBudesonide/Glycopyr/Formoterol15$9,456

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$1,557$243,211204 claims
Novo NordiskOzempic$1,973$199,643165 claims
Boehringer IngelheimJardiance, Synjardy Xr$1,031$171,588183 claims
PfizerEliquis, Premarin$1,275$74,172102 claims
AstraZenecaFarxiga, Breztri Aerosphere$1,394$72,24697 claims
GSKTrelegy Ellipta, Anoro Ellipta$564$64,07268 claims
Johnson & JohnsonXarelto$560$33,50735 claims
BayerKerendia$572$27,61630 claims
MerckJanuvia$406$19,31920 claims
Astellas Pharma US IncMyrbetriq$60$4,98311 claims
Esperion Therapeutics, Inc.Nexlizet$197$4,22011 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$13$3,930541 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,216 internal medicine providers in Tennessee.

Other internal medicine in Dickson

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →